Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-07-25

Clinical Trial Update: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma [Phase 4]

View source ↗

Summary

Phase 4 trial investigating anlotinib in patients with advanced medullary thyroid carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Medullary Thyroid Cancer | Phase 4 | Status: RECRUITING